Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy
and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study
Nef-301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or
ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment,
whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to
Nefecon.